DaVita Divests DMG To Optum, Boosts Kidney Care Services

 | Jun 19, 2019 09:02PM ET

DaVita Inc.’s (NYSE:DVA) Medical Group unit has been sold to Optum for $4.3 billion. This is expected to improve Davita’s major Kidney Care business, fortifying its foothold in the global renal care market.

Following the announcement, shares of DaVita rose 2% to close at $51.27 on Jun 19.

More on the Acquisition

The divestment, announced in late 2017, was subjected to regulatory approval and other customary closing conditions. Also, the results of DMG’s business operations have been reported as discontinued.

Notably, DaVita Medical Group (“DMG”) has now become part of OptumCare — a sub-segment of Optum — the acquiring company’s health services segment. The combination aims to improve care quality and patient satisfaction through ambulatory care delivery systems enabled by information technology and supportive clinical services.

Resultantly, DaVita will continue to own and operate its U.S. and international Kidney Care businesses.

How Does DaVita Stand to Gain?

Completion of the DMG divestment will now enable DaVita to focus on its Kidney Care wing, a significant contributor to the company’s top line. In fact, in the last reported quarter, the segment generated $382 million of revenues.

As an operating division of DaVita, DaVita Kidney Care focuses on setting worldwide standards for clinical, social and operational practices in kidney care. The latest development will boost the segment’s key services like in-center hemodialysis, home hemodialysis, peritoneal dialysis, kidney transplant, urology, diabetology and vascular access surgery.

Notably, the company has focused on expanding its Kidney Care business through continuous acquisition of dialysis centers and businesses. In fact, in the recent past, the company opened a 150,000 square-foot campus for DaVita Labs in DeLand, FL, with a view to serve DaVita dialysis clinics and their patients, marking its only laboratory in the United States. (Read More: .

DENTSPLY’s long-term earnings growth rate is expected at 11.5%.

Masimo’s long-term earnings growth rate is projected at 16.1%.

CONMED’s long-term earnings growth rate is estimated at 13.3%.

Will you retire a millionaire?

One out of every six people retires a multimillionaire. Get smart tips you can do today to become one of them in a new Special Report, “7 Things You Can Do Now to Retire a Multimillionaire.”

Get The News You Want
Read market moving news with a personalized feed of stocks you care about.
Get The App

Zacks Investment Research

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

Sign out
Are you sure you want to sign out?
NoYes
CancelYes
Saving Changes